Development Stage and Anticipated Milestones Therapeutic Indication Antibody Program IND Enabling Phase 1 Phase 2 Phase 3 Rosnilimab (Pathogenic T cell depleter) ANB033 (CD122 antagonist) Celiac Disease Rheumatoid Arthritis
P1b to initiate in Q1 2026 Eosinophilic Esophagitis Late-breaking data presented at ACR 2025 Update in H1 2026 on P3 advancement P1 in healthy volunteers ongoing ANB101 (BDCA2 modulator) Inflammatory Disease
Development Stage and Anticipated Milestones Therapeutic Indication Antibody Program IND Enabling Phase 1 Phase 2 Phase 3 1L MMR Deficient Endometrial Cancer (chemo-free regimen) 1L Endometrial Cancer Approved in US and ex-US 2L dMMR/MSI-H Endometrial Cancer Approved in US and ex-US2 Approved in US Jemperli 1 (PD-1 antagonist) Imsidolimab (IL-36R antagonist) dMMR/MSI-H Pan Tumors dMMR/MSI-H Locally-Advanced Rectal Cancer dMMR/MSI-H Perioperative Colon Cancer Neoadjuvant MMRp/MSS Colon Cancer Locally-Advanced HNSCC 3 Generalized Pustular Psoriasis AZUR-1 Top-line data H2 2026 5 AZUR-2 Est. primary comp. 2028 4 AZUR-4 Est. primary comp. 2026 4 JADE Top-line data 2027/2028 6 FDA BLA Filed Dec. 2025 Commercial DOMENICA Est. primary comp. 2026 4
1. Not-exhaustive, does not include ADC combination opportunities (P2 combination data to be shared in H1 2026); 2. Registrational studies also ongoing in China and Japan; 3. HSNCC - Head and neck squamous cell carcinomas; 4. Per clinicaltrials.gov estimated primary completion date; 5. GSK Q3 2025 earnings; 6. Nov. 2025 Guggenheim conference remarks